Cargando…

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

OBJECTIVES: Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism. We evaluated the efficacy and safety of long‐acting pasireotide during a long‐term extension study in patients with CD. DESIGN: Open‐label extension to a 12‐month Phase III s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Petersenn, Stephan, Biller, Beverly M. K., Kadioglu, Pinar, De Block, Christophe, T'Sjoen, Guy, Vantyghem, Marie‐Christine, Tauchmanova, Libuse, Wojna, Judi, Roughton, Michael, Lacroix, André, Newell‐Price, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899900/ https://www.ncbi.nlm.nih.gov/pubmed/31465533 http://dx.doi.org/10.1111/cen.14081

Ejemplares similares

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience
por: ŞAHİN, Serdar, et al.
Publicado: (2021)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
por: Fleseriu, Maria, et al.
Publicado: (2013)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease
por: Petersenn, S, et al.
Publicado: (2014)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
por: Gadelha, Mônica, et al.
Publicado: (2022)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
por: Zhao, Nairui, et al.
Publicado: (2020)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

A prospective longitudinal study of Pasireotide in Nelson’s syndrome
por: Daniel, Eleni, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sivqq3bjf7hnafclp8r37gv92a